BioSpace News Archive

According to Mortality Due to Cancer 2020: Benchmarking Cancer Mortality in Canada, a new study examining the performance of Canada and its provinces on a number of health indicators, including mortality due to cancer, Canada earns a “B” mark when it comes to overall mortality due to cance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184.

Veeva Systems (NYSE: VEEV) today announced that Integra LifeSciences, a global leader in regenerative technologies, neurosurgical, and extremity orthopedic solutions, has selected Veeva Vault CDMS to provide electronic data capture (EDC), coding, data cleaning, and reporting for future clinical trials.

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC).

HORIBA Medical, a leading global diagnostic company providing solutions in chemistry, hematology and hemostasis, today announced that it has obtained U.S. Food and Drug Administration (FDA) and Health Canada clearance in North America for its next generation clinical chemistry system, the Yumizen C1200.

The combined company will improve access to health economics and outcomes research (HEOR), real world evidence (RWE) and market access services for researchers in the life sciences

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is de

Abiomed announces the achievement of two milestones in the development of small bore access for the Impella heart pump.

Naveris, a healthcare company dedicated to improving patient care through early detection of virus-related cancers, today announced the close of its expanded Series A financing, bringing the total raised to over $19 million since the company’s inception.

NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer.